《大行報告》匯豐研究下調百濟神州(06160.HK)目標價至195元 評級維持「買入」
匯豐研究發表研報指,百濟神州(06160.HK)的核心產品「百悅澤」和「百澤安」去年分別錄得銷售額5.65億及4.23億美元,超出預期,估計在百悅澤海外市場份額增長的支持下,強勁的銷售勢頭將持續,因此將百悅澤今明兩年銷售額預測上調7%及12%,預計於2023至2025年銷售額將分別達到9.59億、14.21億和18.52億美元。
該行並將百澤安2023至2024年銷售額預測上調8%至14%,預計2023至2025年銷售額分別為5.7億、7.52億及10.29億美元,相信公司手持的45億美元現金足以應付未來2至3年經營,又估計百悅澤將於今年上半年在中國取得1L CLL/SLL和WM的批准,並在加拿大和澳洲上市,未來取得對各種腫瘤的治療數據,亦有助於百濟神州進行進一步臨床研發。
匯豐研究維持對百濟神州的「買入」評級,但將目標價從204元下調至195元,今明兩年收入預測上調3%至6%,並下調2025至2028年長期預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.